Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104
Sponsor: Erasmus Medical Center
Summary
The goal of this clinical trial is to test ISA104 in patients with chronic hepatitis B. The main question\[s\] it aims to answer are: * How safe is ISA104? * Does ISA104 induce immunity against hepatitis B virus? Different doses of the vaccine ISA104 will be administered to participants. These participants are chronic HBV patients being actively treated with antiviral drugs. Researchers will compare the ISA104 vaccine to a placebo.
Official title: Phase I/II Study to Determine the Safety, Immunogenicity and Efficacy of the Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2023-08-04
Completion Date
2027-03-01
Last Updated
2026-09-15
Healthy Volunteers
No
Conditions
Interventions
ISA104
SLP vaccine
Placebo
Saline solution (0.9% NaCl)
Locations (1)
Erasmus MC
Rotterdam, Netherlands